Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (271-280 of 466) with videos related to

Pageof 47
Sort By:
The Journal of Pathology|March 4, 2025
The significance of PAX5 in Merkel cell carcinomaEmil Chteinberg, Julia Kolarova, Julia Vogt, et al.
Blood|April 19, 2011
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemiaWilliam G Wierda, Thomas J Kipps, Jan Dürig, et al.
Leukemia & Lymphoma|January 15, 2016
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trialClemens M Wendtner, Michael Hallek, Graeme A M Fraser, et al.
Haematologica|August 29, 2015
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)Paula Cramer, Susanne Isfort, Jasmin Bahlo, et al.
American Journal of Hematology|June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.
Journal of Cancer Research and Clinical Oncology|January 17, 2025
Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case reportCarolin Seeling, Sonja Dahlum, Ralf Marienfeld, et al.
British Journal of Haematology|June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trialsJeffrey Jones, Anthony Mato, Steven Coutre, et al.
Leukemia & Lymphoma|April 26, 2013
Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemiaG Doreen te Raa, Jitka Malcikova, Sarka Pospisilova, et al.
Leukemia|February 2, 2021
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4<sup>+</sup> T cells in chronic lymphocytic leukemiaPhilipp M Roessner, Laura Llaó Cid, Ekaterina Lupar, et al.
Blood|April 12, 2012
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trialPeter Dreger, Hartmut Döhner, Fabienne McClanahan, et al.
Pageof 47

Showing results (271-280 of 466) with videos related to

Sort By:
Pageof 47
The Journal of Pathology|March 4, 2025
The significance of PAX5 in Merkel cell carcinomaEmil Chteinberg, Julia Kolarova, Julia Vogt, et al.
Blood|April 19, 2011
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemiaWilliam G Wierda, Thomas J Kipps, Jan Dürig, et al.
Leukemia & Lymphoma|January 15, 2016
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trialClemens M Wendtner, Michael Hallek, Graeme A M Fraser, et al.
Haematologica|August 29, 2015
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)Paula Cramer, Susanne Isfort, Jasmin Bahlo, et al.
American Journal of Hematology|June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.
Journal of Cancer Research and Clinical Oncology|January 17, 2025
Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case reportCarolin Seeling, Sonja Dahlum, Ralf Marienfeld, et al.
British Journal of Haematology|June 7, 2018
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trialsJeffrey Jones, Anthony Mato, Steven Coutre, et al.
Leukemia & Lymphoma|April 26, 2013
Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemiaG Doreen te Raa, Jitka Malcikova, Sarka Pospisilova, et al.
Leukemia|February 2, 2021
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4<sup>+</sup> T cells in chronic lymphocytic leukemiaPhilipp M Roessner, Laura Llaó Cid, Ekaterina Lupar, et al.
Blood|April 12, 2012
Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trialPeter Dreger, Hartmut Döhner, Fabienne McClanahan, et al.
Pageof 47